NEW YORK (GenomeWeb News) – DxS said today that it plans to double the size of its Manchester, UK, manufacturing facility and to hire an undisclosed amount of new staff “over the coming months.”
 
The company said that the increase in capacity is the result of growing demand for its TheraScreen K-RAS assay, which determines patients’ K-RAS mutation status.
 
DxS said that the assay is the “preferred method” for K-RAS mutation screening for Amgen's Vectibix colorectal cancer therapy.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.